Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database

• Published in: Diabetes therapy 2020-02, Vol.11 (2), p.535-548
• Main Authors: Emery, Corinne, Torreton, Elodie, Dejager, Sylvie, Levy-Bachelot, Laurie, Bineau, Sébastien, Detournay, Bruno
• Format: Article
• Language: English
• Subjects: Cardiology; Costs; Diabetes; Drug therapy; Economic aspects; Endocrinology; Evaluation; Expenditures; Hypoglycemic agents; Inhibitor drugs; Internal Medicine; Longitudinal studies; Medical care, Cost of; Medicine; Medicine & Public Health; Original Research; Patient outcomes; Patients; Public health; Type 2 diabetes
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-020-00760-x

Introduction Diabetes is a growing epidemic that imposes a substantial economic burden on healthcare systems. This study aimed to evaluate the cost of managing type 2 diabetes (T2D) with dipeptidyl peptidase 4 inhibitors (DPP4Is) using real-world data. Method This longitudinal study used data from the French EGB (Echantillon Généraliste des Bénéficiaires) database. The annual average direct healthcare cost of treating patients with T2D was calculated 3 years prior and 3 years after initiation of DPP4I therapy. Actual total ambulatory and hospital care expenditure for the 3 years after DPP4I initiation was compared to projected costs. The distribution of costs across all care modalities was assessed over the 6-year period. Results Ambulatory and hospital care expenditure data for 919 patients with T2D starting DPP4I therapy alone or in combination in 2013 were analyzed. A total of 526 patients (57.2%) were still being treated with DPP4I 3 years after DPP4I initiation. Regardless of the treatment regimen, the ambulatory and hospital care costs increased above projected costs in the first year following DPP4I initiation, and then declined during the second and third years to levels in line with or below projected values for patients using DPP4Is as an add-on therapy. The increase in total expenditure in the first year following DPP4I initiation and the subsequent decline in costs in the second and third years were both associated with general trends in consumption across all aspects of patient care. Conclusion Despite an initial increase in healthcare expenditure, concomitant with reevaluation of patient care, this study showed that initiation of DPP4Is as an add-on therapy in French patients with T2D was associated with care expenditure that was in line or below predicted values within the 3 years following treatment initiation. Additional studies are required to evaluate the economic impact of the long-term treatment benefits.